Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cornelis J M Melief

Showing results (1-10 of 189) with videos related to

Pageof 19
Sort By:
Cancer Journal (Sudbury, Mass.)|September 29, 2011
Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virusCornelis J M Melief
Cancer Discovery|July 13, 2012
Selective activation of oxygen-deprived tumor-infiltrating lymphocytes through local intratumoral delivery of CD137 monoclonal antibodiesCornelis J M Melief
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2013
"License to kill" reflects joint action of CD4 and CD8 T cellsCornelis J M Melief
European Journal of Immunology|September 30, 2003
Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?Cornelis J M Melief
Cell Reports. Medicine|October 19, 2022
Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?Cornelis J M Melief
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 17, 2012
Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccineCornelis J M Melief
The New England Journal of Medicine|May 14, 2015
Mutation-specific T cells for immunotherapy of gliomasCornelis J M Melief
Nature Materials|May 26, 2018
Smart delivery of vaccinesCornelis J M Melief
The New England Journal of Medicine|June 1, 2022
T-Cell Immunotherapy against Mutant KRAS for Pancreatic CancerCornelis J M Melief
European Journal of Human Genetics : EJHG|May 12, 2005
Safety in numbersCornelis J M Melief
Pageof 19

Showing results (1-10 of 189) with videos related to

Sort By:
Pageof 19
Cancer Journal (Sudbury, Mass.)|September 29, 2011
Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virusCornelis J M Melief
Cancer Discovery|July 13, 2012
Selective activation of oxygen-deprived tumor-infiltrating lymphocytes through local intratumoral delivery of CD137 monoclonal antibodiesCornelis J M Melief
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2013
"License to kill" reflects joint action of CD4 and CD8 T cellsCornelis J M Melief
European Journal of Immunology|September 30, 2003
Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?Cornelis J M Melief
Cell Reports. Medicine|October 19, 2022
Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?Cornelis J M Melief
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 17, 2012
Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccineCornelis J M Melief
The New England Journal of Medicine|May 14, 2015
Mutation-specific T cells for immunotherapy of gliomasCornelis J M Melief
Nature Materials|May 26, 2018
Smart delivery of vaccinesCornelis J M Melief
The New England Journal of Medicine|June 1, 2022
T-Cell Immunotherapy against Mutant KRAS for Pancreatic CancerCornelis J M Melief
European Journal of Human Genetics : EJHG|May 12, 2005
Safety in numbersCornelis J M Melief
Pageof 19